Stockscreener 앱 받기
5.56
3.93%
0.21
전일 마감가:
$5.35
열려 있는:
$5.72
하루 거래량:
5.73M
Relative Volume:
0.72
시가총액:
$433.99M
수익:
-
순이익/손실:
$-209.96M
주가수익비율:
-1.7595
EPS:
-3.16
순현금흐름:
$-176.27M
1주 성능:
+5.10%
1개월 성능:
-55.16%
6개월 성능:
-60.57%
1년 성능:
-46.02%
1일 변동 폭
$5.35
$5.84
1주일 범위
$4.49
$5.84
52주 변동 폭
$2.68
$17.00
레플리뮨 Stock (REPL) Company Profile
명칭
Replimune Group Inc
전화
(781) 222-9600
주소
500 UNICORN PARK, WOBURN, MA
REPL을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
REPL
Replimune Group Inc
|
5.56 | 417.60M | 0 | -209.96M | -176.27M | -3.16 |
|
VRTX
Vertex Pharmaceuticals Inc
|
392.79 | 100.07B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
580.41 | 59.99B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
448.91 | 58.03B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
653.83 | 39.93B | 3.06B | 1.28B | -614.78M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
321.36 | 36.82B | 3.81B | -644.79M | -669.77M | -6.24 |
레플리뮨 Stock (REPL) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-07-30 | 업그레이드 | Cantor Fitzgerald | Neutral → Overweight |
| 2025-07-23 | 다운그레이드 | BMO Capital Markets | Outperform → Underperform |
| 2025-07-23 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2025-07-23 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2025-07-22 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2025-07-22 | 다운그레이드 | Leerink Partners | Outperform → Market Perform |
| 2025-07-22 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2025-07-22 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2025-06-20 | 개시 | Cantor Fitzgerald | Overweight |
| 2024-08-28 | 개시 | ROTH MKM | Buy |
| 2023-04-17 | 재개 | Piper Sandler | Overweight |
| 2021-11-19 | 개시 | Piper Sandler | Overweight |
| 2021-10-15 | 재개 | BTIG Research | Buy |
| 2020-11-17 | 개시 | BTIG Research | Buy |
| 2020-11-02 | 개시 | Jefferies | Buy |
| 2020-10-15 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2020-07-01 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2020-05-05 | 개시 | Barclays | Overweight |
| 2019-09-04 | 개시 | ROTH Capital | Buy |
| 2019-07-23 | 개시 | Chardan Capital Markets | Buy |
| 2019-07-12 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2019-07-08 | 개시 | H.C. Wainwright | Buy |
| 2019-04-25 | 개시 | Wedbush | Outperform |
| 2019-01-23 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2018-08-14 | 개시 | JP Morgan | Overweight |
| 2018-08-14 | 개시 | Leerink Partners | Outperform |
모두보기
레플리뮨 주식(REPL)의 최신 뉴스
Lawsuit filed for Investors who lost money with shares of Replimune Group, Inc. (NASDAQ: REPL) - openPR.com
Replimune (REPL) Faces Securities Class Action Following - GlobeNewswire
Shareholders of Replimune Group, Inc. (REPL): Protect Your Rights Before September 22, 2025Contact Levi & Korsinsky - ACCESS Newswire
Faruqi & Faruqi Reminds Replimune Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of September 22, 2025REPL - MarketScreener
Class Action Announcement for Replimune Group, Inc. (REPL): Kessler Topaz Meltzer & Check, LLP Announces that a Securities Class Action Lawsuit Has Been Filed Against Replimune Group, Inc. - MarketScreener
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of September 22, 2025 in Replimune Group, Inc. LawsuitREPL - WV News
Replimune Group Stock Soars 17.76% Amid FDA Rejection Lawsuit - AInvest
Momentum divergence signals in Replimune Group Inc. chart2025 Biggest Moves & Safe Swing Trade Setups - Newser
Replimune Group’s SWOT analysis: oncology biotech stock faces FDA hurdles - Investing.com
Replimune Group, Inc. shares rise 11.59% after-hours following securities class action lawsuits. - AInvest
REPL LAWSUIT ALERT: Levi & Korsinsky Notifies Replimune Group, Inc. Investors of a Class - Bluefield Daily Telegraph
REPL LAWSUIT ALERT: Levi & Korsinsky Notifies Replimune - GlobeNewswire
REPL INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC - GlobeNewswire
REPL INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Replimune Group, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - GlobeNewswire Inc.
REPL Investors Have Opportunity to Lead Replimune Group, Inc. Securities Lawsuit First Filed by The Rosen Law Firm - cnhinews.com
Class Action Announcement for Replimune Group, Inc. (REPL): - GlobeNewswire
REPL LAWSUIT ALERT: The Gross Law Firm Notifies Replimune Group, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - WV News
The Gross Law Firm Reminds Shareholders of a Lead Plaintiff - GlobeNewswire
Shareholders who lost money on Replimune Group, Inc. - GlobeNewswire
INVESTOR ALERT: Class Action Lawsuit Filed on Behalf of - GlobeNewswire
Did You Lose Money on Replimune Group, Inc. (REPL)? Levi & Korsinsky Urges Investors to Act Before September 22, 2025 - ACCESS Newswire
REPL Stock News: Investors with Large Losses Should Contact Robbins LLP for Information About Leading the Replimune Group, Inc. Class Action Lawsuit - The Malaysian Reserve
SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Replimune - GlobeNewswire
Replimune Group, Inc. Sued for Securities Law ViolationsInvestors Should Contact Levi & Korsinsky for More InformationREPL - PR Newswire
Bragar Eagel & Squire, P.C. Reminds Investors of Class - GlobeNewswire
Replimune (REPL) Faces Securities Class Action Following Stock’s Collapse Amid FDA’s Rejection of Melanoma Drug - GlobeNewswire Inc.
Investor Alert: Deadline Approaching to Join Replimune Group, Inc. (REPL) Class ActionContact Levi & Korsinsky - ACCESS Newswire
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Replimune Group, Inc. of Class Action Lawsuit and Upcoming DeadlinesREPL - PR Newswire
Class Action Filed Against Replimune Group, Inc. (REPL)September 22, 2025 Deadline to JoinContact The Gross Law Firm - PR Newswire
SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A - GlobeNewswire
Shareholders who lost money on Replimune Group, Inc. (NASDAQ: REPL) Should Contact Wolf Haldenstein Immediately as Lead Plaintiff Deadline is September 22nd - Morningstar
Zurcher Kantonalbank Zurich Cantonalbank Boosts Stock Holdings in Replimune Group, Inc. (NASDAQ:REPL) - Defense World
Investors in Replimune Group, Inc. (REPL): Protect Your RightsContact Levi & Korsinsky Before September 22, 2025 - ACCESS Newswire
Replimune Group, Inc. (REPL) Class Action Lawsuit: Levi & Korsinsky Reminds Investors of September 22, 2025 Deadline - ACCESS Newswire
Key resistance and support levels for Replimune Group Inc.Downside Risk Evaluation and Stock Analysis - Newser
Visualizing Replimune Group Inc. stock with heatmapsEntry Timing with Downside Risk Analysis - Newser
Securities Lawsuit Alert: Replimune Group, Inc. (REPL) InvestorsContact Levi & Korsinsky Before September 22, 2025 - ACCESS Newswire
Shareholders of Replimune Group, Inc. Should Contact Levi & - GlobeNewswire
Levi & Korsinsky Reminds Replimune Group, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of September 22, 2025REPL - PR Newswire
Replimune Group Reports Increased Losses Amid Rising R&D Costs - TipRanks
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Replimune - Stockhouse
ROSEN, THE FIRST FILING FIRM, Encourages Replimune Group, - GlobeNewswire
Replimune Group Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Replimune Group (REPL) Reports Wider-than-Expected Quarterly Los - GuruFocus
Replimune Group: The Prospects For FDA Approval After Rejection (REPL) - Seeking Alpha
Shareholders that lost money on Replimune Group, Inc.(REPL) should contact The Gross Law Firm about pending Class ActionREPL - Barchart.com
Replimune Reports Fiscal First Quarter 2026 Financial Results an - GuruFocus
Biotech Replimune's Q1 net loss widens, cash balance drops - MarketScreener
Replimune Group, Inc. SEC 10-Q Report - TradingView
Replimune's Melanoma Drug Hits FDA Roadblock: Q1 Losses Widen to $86.7M as Clinical Trials Advance - Stock Titan
Replimune Group (REPL) Expected to Announce Earnings on Thursday - Defense World
레플리뮨 (REPL) 재무 분석
매출
순이익
현금흐름
주당 순 이익
레플리뮨 주식 (REPL) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Xynos Konstantinos | Chief Medical Officer |
May 20 '25 |
Sale |
8.06 |
7,952 |
64,093 |
146,933 |
| Schwendenman Andrew | Chief Accounting Officer |
May 20 '25 |
Sale |
8.05 |
3,287 |
26,460 |
68,284 |
| Patel Sushil | Chief Executive Officer |
May 20 '25 |
Sale |
8.06 |
25,105 |
202,346 |
343,576 |
| Hill Emily Luisa | Chief Financial Officer |
May 20 '25 |
Sale |
8.05 |
2,535 |
20,407 |
143,522 |
| Sarchi Christopher | Chief Commercial Officer |
May 20 '25 |
Sale |
8.05 |
3,749 |
30,179 |
128,296 |
| Patel Sushil | Chief Executive Officer |
Dec 16 '24 |
Sale |
12.42 |
10,000 |
124,200 |
202,014 |
0.41%
0.88%
자본화:
|
볼륨(24시간):